Jan 12, 2026 07:08AM AXGN reports preliminary Q4 revenue of $59.9 million, up 21%

Dec 12, 2025 06:21AM AxoGen, Inc. (AXGN) PT Raised to $40 at Leerink Partners

Dec 8, 2025 06:46AM AxoGen, Inc. (AXGN) PT Raised to $39 at H.C. Wainwright

Dec 5, 2025 06:28AM AxoGen, Inc. (AXGN) PT Raised to $37 at Canaccord Genuity

Dec 4, 2025 10:02AM AxoGen, Inc. (AXGN) PT Raised to $36 at Raymond James

Dec 4, 2025 09:19AM Mizuho Reiterates Outperform Rating on AxoGen, Inc. (AXGN)

Dec 4, 2025 07:27AM AxoGen, Inc. (AXGN) PT Raised to $36 at Jefferies

Dec 4, 2025 04:08AM AxoGen (AXGN) 'Has Truly Differentiated Products' - Citizens

Dec 1, 2025 05:12AM Mizuho Starts AxoGen, Inc. (AXGN) at Outperform

Oct 30, 2025 05:37AM AxoGen, Inc. (AXGN) PT Raised to $28 at Leerink Partners

Oct 30, 2025 04:17AM AxoGen, Inc. (AXGN) PT Raised to $34 at Citizens: 'Truly Differentiated Products'

Oct 29, 2025 01:26PM AxoGen, Inc. (AXGN) PT Raised to $27 at Canaccord Genuity

Oct 29, 2025 07:28AM AxoGen (AXGN) Tops Q3 EPS by 5c

Oct 2, 2025 06:28AM Canaccord Genuity Reiterates Buy Rating on AxoGen, Inc. (AXGN)

Oct 1, 2025 01:20PM Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'

Sep 30, 2025 06:07AM H.C. Wainwright Reiterates Buy Rating on AxoGen, Inc. (AXGN)

Aug 25, 2025 11:12AM AxoGen (AXGN) call put ratio 1 call to 5 puts with a focus on September 15 puts as share price down 9%

Aug 25, 2025 11:01AM Raymond James on AxoGen, Inc. (AXGN): 'PDUFA Timing Pushout Adds Drama, but We Still Expect Approval'

Aug 25, 2025 06:40AM Axogen receives three-month FDA review extension for Avance Nerve Graft

Aug 11, 2025 07:05AM Cantor Fitzgerald Reiterates Overweight Rating on AxoGen, Inc. (AXGN)

Aug 5, 2025 04:19PM AxoGen, Inc. (AXGN) PT Lowered to $20 at Raymond James

Aug 5, 2025 12:39PM AxoGen, Inc. (AXGN) PT Raised to $25 at Jefferies

Aug 5, 2025 07:15AM AxoGen (AXGN) Tops Q2 EPS by 6c, provides guidance

Jul 29, 2025 01:02PM Axogen (AXGN) explores potential sale after takeover interest - source

Jul 22, 2025 02:56PM AxoGen (AXGN) August 12.50 and 17.5 calls active as share price up 6%

Jun 2, 2025 06:44AM AxoGen, Inc. (AXGN) PT Lowered to $23 at Cantor Fitzgerald

May 12, 2025 04:10PM AxoGen, Inc. (AXGN) PT Lowered to $24 at Canaccord Genuity

May 8, 2025 07:20AM AxoGen (AXGN) Misses Q1 EPS by 4c

May 8, 2025 07:00AM AxoGen (AXGN) Announces CFO Change

Mar 17, 2025 09:26AM Lake Street Capital Markets Starts AxoGen, Inc. (AXGN) at Buy

Mar 17, 2025 07:38AM Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer

Mar 10, 2025 07:11AM AxoGen, Inc. (AXGN) PT Maintained at $24 at Cantor Fitzgerald

Mar 5, 2025 08:36AM Cantor Fitzgerald Reiterates Overweight Rating on AxoGen, Inc. (AXGN)

Mar 5, 2025 05:21AM Citizens JMP Reiterates Market Outperform Rating on AxoGen, Inc. (AXGN)

Feb 26, 2025 05:05AM AxoGen, Inc. (AXGN) PT Raised to $26 at Citizens JMP

Feb 25, 2025 04:39PM AxoGen, Inc. (AXGN) PT Raised to $26 at Canaccord Genuity

Feb 25, 2025 04:00PM AxoGen, Inc. (AXGN) PT Raised to $25 at Raymond James

Feb 25, 2025 01:07PM AxoGen, Inc. (AXGN) PT Raised to $25 at Leerink Partners

Feb 25, 2025 10:41AM AxoGen, Inc. (AXGN) PT Raised to $24 at Cantor Fitzgerald

Feb 25, 2025 07:16AM AxoGen (AXGN) Tops Q4 EPS by 4c

Feb 3, 2025 08:08AM AxoGen (AXGN) Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 3, 2025 06:32AM AxoGen, Inc. (AXGN) PT Raised to $22 at Canaccord Genuity

Jan 10, 2025 08:02AM AxoGen (AXGN) Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

Nov 7, 2024 08:29AM AxoGen (AXGN) Tops Q3 EPS by 6c

Sep 6, 2024 07:00AM AxoGen (AXGN) Completes Submission of BLA to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024 07:19AM AxoGen (AXGN) Tops Q2 EPS by 11c, provides guidance

Aug 8, 2024 07:05AM AxoGen (AXGN) Appoints Michael Dale as CEO